InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,543.22
(
1.61%
)
US TECH 100
19,002.00
(
2.66%
)
Dow Jones
40,563.06
(
1.39%
)
Brent Oil
80.41
(
-0.09%
)
Bitcoin
57,193.38
(
-0.60%
)
Post# of 252897
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 835
Posts 120287
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 55873

Saturday, 12/08/2007 6:28:34 PM

Saturday, December 08, 2007 6:28:34 PM

Post# of 252897
MNTA’s M118 vs oral FXa inhibitors:

A poster on SI just asked why M118 is a better drug than Rivaroxaban. The answer is: it’s not better… it’s different.

M118 inhibits both FXa and FIIa (#msg-24393520), while Rivaroxaban inhibits FXa only. This makes Rivaroxaban unsuitable for use in such indications as ACS and stable angina where FIIa inhibition is obligatory.

On the other hand, for chronic prevention of DVT and chronic prevention of stoke in patients with AF, Rivaroxaban and other oral FXa inhibitors such as Apixaban enjoy the convenience of being a pill.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up